Other Events ·
PolyPid terminates agreement with Advanz Pharma, regaining full European commercialization rights for D-PLEX100
PYPDPolyPid Ltd.
PolyPid Ltd. announced the mutual termination of its exclusive License, Distribution and Supply Agreement with Advanz Pharma for D-PLEX₁₀₀ in Europe, effective October 1, 2026. Consequently, PolyPid has regained full European commercialization rights for the drug. The company highlighted recent milestones including successful Phase 3 SHIELD II trial results, NDA submission to the FDA, EMA submission, and a North American partnership with Azurity Pharmaceuticals. This strategic move expands PolyPid's global commercialization opportunities for D-PLEX₁₀₀ in the surgical site infection market. PolyPid Ltd. is an innovative biopharmaceutical company developing long-acting, controlled-release drugs for surgical care and metabolic diseases.